How to think about Trump’s pharma tariffs — before they hit

What's new in pharma

April 18, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | How to think about Trump's pharma tariffs — before they hit There are a host of factors to consider when assessing what the levies will mean for both drugmakers and consumers. By Ed Silverman Opinion: Five priorities to remake the FDA in a time of deep uncertainty   Respect review teams, modernize post-market product evaluation, and three other priorities for FDA Commissioner Marty Makary. By Luciana Borio and Phil Krause STAT+ | Health care industry, worried millions could lose ACA insurance, pushes for Trump to delay changes Hospitals and health insurers are alarmed at the prospect of an increase in the number of people without health insurance. By Bob Herman Kayla Bartkowski/Getty Images STAT+ | Makary says FDA will remove pharma representatives from advisory panels Representatives from pharma and other industries already play a more limited role in advising the FDA. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser